Using NGS, researchers discovered many new genes with low or moderate risk for hereditary cancers. As such, whole-exome sequencing (WES) and whole-genome sequencing (WGS) powered multi-gene panels ...

We’ve been first-to-market with a wide variety of tests and technologies, including clinical exome and hereditary cancer panels. We strive to develop the most accurate, highest quality tests ...

A new comprehensive hereditary cancer solution offers genetic counseling and multigene panels to enhance early detection of disease's like brain cancer.

Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including hereditary cancer tests that assess the risk for ...

This study reports a 3-year experience with mainstreaming hereditary cancer gene panel testing at Kaiser Permanente Southern California. The study compared demographic characteristics, cancer ...

Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

and a selection of multigene panels to choose from. This advanced offering identifies risk and disease-causing variants associated with hereditary cancer syndromes across multiple organ systems ...